Advertisement

Hepatology International

, Volume 3, Issue 2, pp 323–333 | Cite as

Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL)

  • Gamal Shiha
  • Shiv Kumar Sarin
  • Alaa Eldin Ibrahim
  • Masao Omata
  • Ashish Kumar
  • Laurentius A. Lesmana
  • Nancy Leung
  • Nurdan Tozun
  • Saeed Hamid
  • Wasim Jafri
  • Hitoshi Maruyama
  • Pierre Bedossa
  • Massimo Pinzani
  • Yogesh Chawla
  • Gamal Esmat
  • Wahed Doss
  • Taher Elzanaty
  • Puja Sakhuja
  • Ahmed Medhat Nasr
  • Ashraf Omar
  • Chun-Tao Wai
  • Ahmed Abdallah
  • Mohsen Salama
  • Abdelkhalek Hamed
  • Ayman Yousry
  • Imam Waked
  • Medhat Elsahar
  • Amr Fateen
  • Sherif Mogawer
  • Hassan Hamdy
  • Reda Elwakil
  • Jury of the APASL Consensus Development Meeting 29 January 2008 on Liver Fibrosis With Without Hepatitis B or C
APASL Guidelines

Abstract

Liver fibrosis is a common pathway leading to cirrhosis, which is the final result of injury to the liver. Accurate assessment of the degree of fibrosis is important clinically, especially when treatments aimed at reversing fibrosis are being evolved. Liver biopsy has been considered to be the “gold standard” to assess fibrosis. However, liver biopsy being invasive and, in many instances, not favored by patients or physicians, alternative approaches to assess liver fibrosis have assumed great importance. Moreover, therapies aimed at reversing the liver fibrosis have also been tried lately with variable results. Till now, there has been no consensus on various clinical, pathological, and radiological aspects of liver fibrosis. The Asian Pacific Association for the Study of the Liver set up a working party on liver fibrosis in 2007, with a mandate to develop consensus guidelines on various aspects of liver fibrosis relevant to disease patterns and clinical practice in the Asia-Pacific region. The process for the development of these consensus guidelines involved the following: review of all available published literature by a core group of experts; proposal of consensus statements by the experts; discussion of the contentious issues; and unanimous approval of the consensus statements after discussion. The Oxford System of evidence-based approach was adopted for developing the consensus statements using the level of evidence from 1 (highest) to 5 (lowest) and grade of recommendation from A (strongest) to D (weakest). The consensus statements are presented in this review.

Keywords

Cirrhosis Liver biopsy Noninvasive tools HVPG Ultrasound 

References

  1. 1.
    Grigorescu M. Noninvasive biochemical markers of liver fibrosis. J Gastrointestin Liver Dis 2006;15:149–159PubMedGoogle Scholar
  2. 2.
    Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986;1:523–525. doi: 10.1016/S0140-6736(86)90883-4 PubMedCrossRefGoogle Scholar
  3. 3.
    Hølund B, Poulsen H, Schlichting P. Reproducibility of liver biopsy diagnosis in relation to the size of the specimen. Scand J Gastroenterol 1980;15:329–335PubMedCrossRefGoogle Scholar
  4. 4.
    Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003;39:239–244. doi: 10.1016/S0168-8278(03)00191-0 PubMedCrossRefGoogle Scholar
  5. 5.
    Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898–1906. doi: 10.1053/j.gastro.2005.03.084 PubMedCrossRefGoogle Scholar
  6. 6.
    Grizzi F, Russo C, Franceschini B, Di Rocco M, Torri V, Morenghi E, et al. Sampling variability of computer-aided fractal-corrected measures of liver fibrosis in needle biopsy specimens. World J Gastroenterol 2006;12:7660–7665PubMedGoogle Scholar
  7. 7.
    Dioguardi N, Grizzi F, Franceschini B, Bossi P, Russo C. Liver fibrosis and tissue architectural change measurement using fractal-rectified metrics and Hurst’s exponent. World J Gastroenterol 2006;12:2187–2194PubMedGoogle Scholar
  8. 8.
    Skripenova S, Trainer TD, Krawitt EL, Blaszyk H. Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C. J Clin Pathol 2007;60:321–324. doi: 10.1136/jcp.2005.036020 PubMedCrossRefGoogle Scholar
  9. 9.
    De Groote J, Desmet VJ, Gedigk P, Korb G, Popper H, Poulsen H, et al. A classification of chronic hepatitis. Lancet 1968;2:626–628. doi: 10.1016/S0140-6736(68)90710-1 PubMedGoogle Scholar
  10. 10.
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431–435. doi: 10.1002/hep.1840010511 PubMedCrossRefGoogle Scholar
  11. 11.
    Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289–293. doi: 10.1002/hep.510240201 PubMedCrossRefGoogle Scholar
  12. 12.
    Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–699. doi: 10.1016/0168-8278(95)80226-6 PubMedCrossRefGoogle Scholar
  13. 13.
    Westin J, Lagging LM, Wejstål R, Norkrans G, Dhillon AP. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999;19:183–187. doi: 10.1111/j.1478-3231.1999.tb00033.x PubMedCrossRefGoogle Scholar
  14. 14.
    Matalka II, Al-Jarrah OM, Manasrah TM. Quantitative assessment of liver fibrosis: a novel automated image analysis method. Liver Int 2006;26:1054–1064. doi: 10.1111/j.1478-3231.2006.01341.x PubMedCrossRefGoogle Scholar
  15. 15.
    Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518–526. doi: 10.1053/jhep.2003.50346 PubMedCrossRefGoogle Scholar
  16. 16.
    Lieber CS, Weiss DG, Morgan TR, Paronetto F. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 2006;101:1500–1508. doi: 10.1111/j.1572-0241.2006.00610.x PubMedCrossRefGoogle Scholar
  17. 17.
    Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004;3:8. doi: 10.1186/1476-5926-3-8 PubMedCrossRefGoogle Scholar
  18. 18.
    Rosenberg WM. Rating fibrosis progression in chronic liver diseases. J Hepatol 2003;38:357–360. doi: 10.1016/S0168-8278(03)00010-2 PubMedCrossRefGoogle Scholar
  19. 19.
    Poordad FF. FIBROSpect II: a potential noninvasive test to assess hepatic fibrosis. Expert Rev Mol Diagn 2004;4:593–537. doi: 10.1586/14737159.4.5.593 PubMedCrossRefGoogle Scholar
  20. 20.
    Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935–942. doi: 10.1016/j.jhep.2004.08.008 PubMedCrossRefGoogle Scholar
  21. 21.
    Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867–1873. doi: 10.1373/clinchem.2005.048389 PubMedCrossRefGoogle Scholar
  22. 22.
    Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373–1381. doi: 10.1002/hep.20935 PubMedCrossRefGoogle Scholar
  23. 23.
    Festi D, Capodicasa S, Sandri L, Colaiocco-Ferrante L, Staniscia T, Vitacolonna E, et al. Measurement of hepatic functional mass by means of 13C-methacetin and 13C-phenylalanine breath tests in chronic liver disease: comparison with Child-Pugh score and serum bile acid levels. World J Gastroenterol 2005;11:142–148PubMedGoogle Scholar
  24. 24.
    Di Campli C, Angelini G, Armuzzi A, Nardo B, Zocco MA, Candelli M, et al. Quantitative evaluation of liver function by the methionine and aminopyrine breath tests in the early stages of liver transplantation. Eur J Gastroenterol Hepatol 2003;15:727–732. doi: 10.1097/00042737-200307000-00003 PubMedCrossRefGoogle Scholar
  25. 25.
    Attallah AM, Shiha GE, Omran MM, Zalata KR. A discriminant score based on four routine laboratory blood tests for accurate diagnosis of severe fibrosis and/or liver cirrhosis in Egyptian patients with chronic hepatitis C. Hepatol Res 2006;34:163–169. doi: 10.1016/j.hepres.2005.12.004 PubMedCrossRefGoogle Scholar
  26. 26.
    Iacobellis A, Fusilli S, Mangia A, Clemente R, Festa V, Giacobbe A, et al. Ultrasonographic and biochemical parameters in the non-invasive evaluation of liver fibrosis in hepatitis C virus chronic hepatitis. Aliment Pharmacol Ther 2005;22:769–774. doi: 10.1111/j.1365-2036.2005.02633.x PubMedCrossRefGoogle Scholar
  27. 27.
    Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology 2002;36(5 Suppl 1):S57–S64. doi: 10.1053/jhep.2002.36800 PubMedCrossRefGoogle Scholar
  28. 28.
    Abdel-Wahab MF, Esmat G, Farrag A, el-Boraey YA, Strickland GT. Grading of hepatic schistosomiasis by the use of ultrasonography. Am J Trop Med Hyg 1992;46:403–408PubMedGoogle Scholar
  29. 29.
    Liu CH, Lin JW, Tsai FC, Yang PM, Lai MY, Chen JH, et al. Noninvasive tests for the prediction of significant hepatic fibrosis in hepatitis C virus carriers with persistently normal alanine aminotransferases. Liver Int 2006;26:1087–1094. doi: 10.1111/j.1478-3231.2006.01355.x PubMedCrossRefGoogle Scholar
  30. 30.
    Richter J, Correia Dacal AR, Vergetti Siqueira JG, Poggensee G, Mannsmann U, Deelder A, et al. Sonographic prediction of variceal bleeding in patients with liver fibrosis due to Schistosoma mansoni. Trop Med Int Health 1998;3:728–735PubMedGoogle Scholar
  31. 31.
    Albrecht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V, Eckersley R, et al. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999;353:1579–1583. doi: 10.1016/S0140-6736(98)06373-9 PubMedCrossRefGoogle Scholar
  32. 32.
    Kaneko T, Teshigawara O, Sugimoto H, Hirota M, Inoue S, Takeda S, et al. Signal intensity of the liver parenchyma in microbubble contrast agent in the late liver phase reflects advanced fibrosis of the liver. Liver Int 2005;25:288–293. doi: 10.1111/j.1478-3231.2005.01025.x PubMedCrossRefGoogle Scholar
  33. 33.
    Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003;29:1705–1713. doi: 10.1016/j.ultrasmedbio.2003.07.001 PubMedCrossRefGoogle Scholar
  34. 34.
    Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343–350. doi: 10.1053/j.gastro.2004.11.018 PubMedCrossRefGoogle Scholar
  35. 35.
    de Lédinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006;41:175–179. doi: 10.1097/01.qai.0000194238.15831.c7 PubMedCrossRefGoogle Scholar
  36. 36.
    Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007;5:1214–1220. doi: 10.1016/j.cgh.2007.07.020 PubMedCrossRefGoogle Scholar
  37. 37.
    Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007;102:2589–2600. doi: 10.1111/j.1572-0241.2007.01466.x PubMedCrossRefGoogle Scholar
  38. 38.
    Samonakis DN, Cholongitas E, Thalheimer U, Kalambokis G, Quaglia A, Triantos CK, et al. Hepatic venous pressure gradient to assess fibrosis and its progression after liver transplantation for HCV cirrhosis. Liver Transpl 2007;13:1305–1311. doi: 10.1002/lt.21227 PubMedCrossRefGoogle Scholar
  39. 39.
    Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007;45:1290–1297. doi: 10.1002/hep.21665 PubMedCrossRefGoogle Scholar
  40. 40.
    Kumar A, Sharma P, Sarin SK. Hepatic venous pressure gradient measurement: time to learn!. Indian J Gastroenterol 2008;27:74PubMedGoogle Scholar
  41. 41.
    Groszmann R, Vorobioff JD, Gao H. Measurement of portal pressure: when, how, and why to do it. Clin Liver Dis 2006;10:499–512. doi: 10.1016/j.cld.2006.08.005 PubMedCrossRefGoogle Scholar
  42. 42.
    Groszmann RJ, Wongcharatrawee S. The hepatic venous pressure gradient: anything worth doing should be done right. Hepatology 2004;39:280–282. doi: 10.1002/hep.20062 PubMedCrossRefGoogle Scholar
  43. 43.
    Groszmann RJ, Glickman M, Blei AT, Storer E, Conn HO. Wedged and free hepatic venous pressure measured with a balloon catheter. Gastroenterology 1979;76:253–258PubMedGoogle Scholar
  44. 44.
    Huet PM, Pomier-Layrargues G. The hepatic venous pressure gradient: “remixed and revisited”. Hepatology 2004;39:295–298. doi: 10.1002/hep.20070 PubMedCrossRefGoogle Scholar
  45. 45.
    Boyer TD. Wedged hepatic vein pressure (WHVP): ready for prime time. Hepatology 2006;43:405–406. doi: 10.1002/hep.21118 PubMedCrossRefGoogle Scholar
  46. 46.
    Pinzani M, Gentilini P. Biology of hepatic stellate cells and their possible relevance in the pathogenesis of portal hypertension in cirrhosis. Semin Liver Dis 1999;19:397–410PubMedCrossRefGoogle Scholar
  47. 47.
    Poynard T, Ratziu V, Bedossa P. Appropriateness of liver biopsy. Can J Gastroenterol 2000;14:543–548PubMedGoogle Scholar
  48. 48.
    Rincon D, Ripoll C, Lo Iacono O, Salcedo M, Catalina MV, Alvarez E, et al. Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 2006;101:2269–2274. doi: 10.1111/j.1572-0241.2006.00743.x PubMedCrossRefGoogle Scholar
  49. 49.
    Kumar M, Kumar A, Hissar S, Jain P, Rastogi A, Kumar D, et al. Hepatic venous pressure gradient as a predictor of fibrosis in chronic liver disease because of hepatitis B virus. Liver Int 2008;28:690–698PubMedGoogle Scholar
  50. 50.
    Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132(7):517–524PubMedGoogle Scholar
  51. 51.
    Veldt BJ, Saracco G, Boyer N, Camma C, Bellobuono A, Hopf U, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004;53:1504–1508. doi: 10.1136/gut.2003.038257 PubMedCrossRefGoogle Scholar
  52. 52.
    Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Meta-analysis HCV (on) individual patients’ data Study Group relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006;130:1636–1642. doi: 10.1053/j.gastro.2006.03.014 PubMedCrossRefGoogle Scholar
  53. 53.
    Saller R, Meier R, Brignoli R. The use of silymarin in the treatment of liver diseases. Drugs 2001;61:2035–2063. doi: 10.2165/00003495-200161140-00003 PubMedCrossRefGoogle Scholar
  54. 54.
    Muriel P, Garciapiña T, Perez-Alvarez V, Mourelle M. Silymarin protects against paracetamol-induced lipid peroxidation and liver damage. J Appl Toxicol 1992;12:439–442. doi: 10.1002/jat.2550120613 PubMedCrossRefGoogle Scholar
  55. 55.
    Hakov’a H, Misúrová E. The effect of silymarin and gamma radiation on nucleic acids in rat organs. J Pharm Pharmacol 1993;45:910–912PubMedGoogle Scholar
  56. 56.
    Rambaldi A, Jacobs BP, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C virus liver diseases. Cochrane Database Syst Rev 2007;(4):CD003620Google Scholar
  57. 57.
    Trinchet JC, Coste T, Lévy VG, Vivet F, Duchatelle V, Legendre C, et al. Treatment of alcoholic hepatitis with silymarin A double-blind comparative study in 116 patients. Gastroenterol Clin Biol 1989;13:120–124PubMedGoogle Scholar
  58. 58.
    Stickel F, Schuppan D. Herbal medicine in the treatment of liver diseases. Dig Liver Dis 2007;39:293–304. doi: 10.1016/j.dld.2006.11.004 PubMedCrossRefGoogle Scholar
  59. 59.
    Popper H, Zak FG. Pathologic aspects of cirrhosis. Am J Med 1958;24:593–619. doi: 10.1016/0002-9343(58)90298-5 PubMedCrossRefGoogle Scholar
  60. 60.
    Agarwal BL. Cirrhosis of the liver. BMJ 1968;2:561–562PubMedCrossRefGoogle Scholar
  61. 61.
    Anthony PP, Ishak KG, Nayak NC, Poulsen HE, Scheuer PJ, Sobin LH. The morphology of cirrhosis. Recommendations on definition, nomenclature, and classification by a working group sponsored by the World Health Organization. J Clin Pathol 1978;31:395–414. doi: 10.1136/jcp.31.5.395 PubMedCrossRefGoogle Scholar
  62. 62.
    Huang YH, Shi MN, Zheng WD, Zhang LJ, Chen ZX, Wang XZ. Therapeutic effect of interleukin–10 on CCl4-induced hepatic fibrosis in rats. World J Gastroenterol 2006;12:1386–1391PubMedGoogle Scholar
  63. 63.
    Wanless IR, Nakashima E, Sherman M. Regression of human cirrhosis. Morphologic features and the genesis of incomplete septal cirrhosis. Arch Pathol Lab Med 2000;124:1599–1607PubMedGoogle Scholar
  64. 64.
    Popper H, Elias H. Histogenesis of hepatic cirrhosis studied by the three-dimensional approach. Am J Pathol 1955;31:405–441PubMedGoogle Scholar
  65. 65.
    Pérez-Tamayo R. Cirrhosis of the liver: a reversible disease? Pathol Annu 1979;14:183–213PubMedGoogle Scholar
  66. 66.
    Wang YJ, Lee SD, Hsieh MC, Lin HC, Lee FY, Tsay SH, et al. A double-blind randomized controlled trial of colchicine in patients with hepatitis B virus-related postnecrotic cirrhosis. J Hepatol 1994;21:872–877. doi: 10.1016/S0168-8278(94)80252-1 PubMedCrossRefGoogle Scholar
  67. 67.
    Verma S, Gunuwan B, Mendler M, Govindrajan S, Redeker A. Factors predicting relapse and poor outcome in type I autoimmune hepatitis: role of cirrhosis development, patterns of transaminases during remission and plasma cell activity in the liver biopsy. Am J Gastroenterol 2004;99:1510–1516. doi: 10.1111/j.1572-0241.2004.30457.x PubMedCrossRefGoogle Scholar
  68. 68.
    Muddu AK, Guha IN, Elsharkawy AM, Mann DA. Resolving fibrosis in the diseased liver: translating the scientific promise to the clinic. Int J Biochem Cell Biol 2007;39:695–714. doi: 10.1016/j.biocel.2006.10.006 PubMedCrossRefGoogle Scholar

Copyright information

© Asian Pacific Association for the Study of the Liver 2008

Authors and Affiliations

  • Gamal Shiha
    • 1
  • Shiv Kumar Sarin
    • 1
  • Alaa Eldin Ibrahim
    • 1
  • Masao Omata
    • 1
  • Ashish Kumar
    • 1
  • Laurentius A. Lesmana
    • 1
  • Nancy Leung
    • 1
  • Nurdan Tozun
    • 1
  • Saeed Hamid
    • 1
  • Wasim Jafri
    • 1
  • Hitoshi Maruyama
    • 1
  • Pierre Bedossa
    • 1
  • Massimo Pinzani
    • 1
  • Yogesh Chawla
    • 1
  • Gamal Esmat
    • 1
  • Wahed Doss
    • 1
  • Taher Elzanaty
    • 1
  • Puja Sakhuja
    • 1
  • Ahmed Medhat Nasr
    • 1
  • Ashraf Omar
    • 1
  • Chun-Tao Wai
    • 1
  • Ahmed Abdallah
    • 1
  • Mohsen Salama
    • 1
  • Abdelkhalek Hamed
    • 1
  • Ayman Yousry
    • 1
  • Imam Waked
    • 1
  • Medhat Elsahar
    • 1
  • Amr Fateen
    • 1
  • Sherif Mogawer
    • 1
  • Hassan Hamdy
    • 1
  • Reda Elwakil
    • 1
  • Jury of the APASL Consensus Development Meeting 29 January 2008 on Liver Fibrosis With Without Hepatitis B or C
    • 2
  1. 1.GI and Liver Unit, Internal Medicine Department, Almansoura Faculty of MedicineAlmansoura UniversityAlmansouraEgypt
  2. 2.MansouraEgypt

Personalised recommendations